source
- AstraZeneca signs up to $1.7 billion R&D pact with China’s CSPC, marking second deal in six monthsAstraZeneca announced a new research collaboration with Chinese partner CSPC, valued at up to $1.7 billion. The agreement follows a previous large biobucks deal signed less than six months earlier…
- Scribe Therapeutics files for Nasdaq IPO, testing market appetite for early-stage gene-editing firmsScribe Therapeutics announced it has filed a registration statement to list its shares on the Nasdaq, marking the company’s first step toward a public offering. The filing highlights the growing i…